Oral Cavity Cancer Clinical Trial
Official title:
A Preoperative Window of Opportunity Study to Assess the Modulation of Biomarkers in the Primary Tumor Site of Patients With Resectable Oral Cavity Cancer (OCC) Randomized to Receive Preoperative Treatment With PF-00299804
The objective of this study is to assess the biological effects in the primary tumor following a short, pre-operative course of treatment with PF-00298804 in patients with Oral Cavity Cancer.
Status | Completed |
Enrollment | 13 |
Est. completion date | February 2014 |
Est. primary completion date | February 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Signed, voluntary informed consent provided - Willing and able to comply with scheduled visits, treatment plan, tests, other study procedures - Patient must be diagnosed with histologically confirmed oral cavity squamous cell carcinoma (OCC) (lip, floor of mouth, anterior 2/3 tongue, buccal mucosa, upper and lower gingiva, hard palate and retromolar trigone) considered resectable (T1-4a, N0-2, M0; (without distant metastases)) for whom surgical resection of tumor is planned. Patients with distant metastatic disease or diagnosis of SCCHN may not be enrolled - Must be able to provide a fresh tumor biopsy prior to randomization for histopathological and biomarker evaluation. No anti-neoplastic treatment allowed between obtaining baseline tumor specimen and randomization. Patients who decline an in-house fresh pre-treatment tumor biopsy must give consent to provide a tumor block from an existing diagnostic primary tumor biopsy completed within 90 days of enrolment - Prior treatment with agents targeted to epidermal growth factor receptor is not allowed. - No prior chemotherapy or radiotherapy (to primary site/nodes). - Patient must not have received prior anti-neoplastic treatment within past 2 years - Any treatment-related acute toxicity, including laboratory abnormalities, must have recovered to CTCAE Grade 1 (v.4.0) or baseline, except toxicity not considered a safety risk. - ECOG performance status of 0-2. - Patient must have adequate organ function as determined by the following criteria: - Serum creatinine = 1.5 ULN or a calculated creatinine clearance of = 50 mL/min - Absolute neutrophil count = 1.5 x 109/L - Leukocytes > 3.0 x 109/L - Hemoglobin > 80 g/L - Platelets > 100 x 109/L - Total bilirubin < ULN - AST (SGOT) and ALT (SGPT) < 2.5 x ULN - 12-Lead ECG with normal tracing, or clinically non-significant changes that do not require medical intervention - QTc interval < 470 msec, and without history of Torsades de Pointes or other symptomatic QTc abnormality - A normal LVEF of >50% as measured by ECHO or MUGA within 4 weeks prior to start of study treatment will be required for all patients Exclusion Criteria: - Patients who require segmental mandibulectomy for surgical resection of oral cavity tumor will not be enrolled - Primary site of head and neck carcinoma in nasopharynx, skin, or unknown - Prior or concurrent radiation therapy to tumor at site of planned resection - Any clinically significant gastrointestinal abnormalities, which may impair intake, transit or absorption of PF-00299804 - Requirement for treatment with drugs that are highly dependent on CYP2D6 for metabolism since PF-00299804 is a potent CYP2D6 inhibitor in in vitro assays - Patients currently taking drugs that have a risk of causing Torsades de Pointes - Any acute or chronic medical, psychiatric condition or laboratory abnormality that could increase the risk associated with trial participation or trial drug administration or could interfere with interpretation of trial results and, in the judgment of the investigator, would make the patient inappropriate for entry in the trial - Other serious uncontrolled medical disorder or active infection that would impair the ability to receive study treatment as determined by investigator - Dementia or significantly altered mental status that would limit the ability to obtain informed consent and compliance with the requirements of this protocol - Patients breastfeeding or pregnant are excluded. All female patients with reproductive potential must have a negative pregnancy test within 72 hours prior to treatment. - Patients of reproductive potential or their partners must agree to use effective contraception while receiving trial treatment and for at least 3 months thereafter. - Current enrollment in another therapeutic clinical trial - Inability/lack of willingness to comply with visits, treatment plans, protocol assessments or laboratory tests |
Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Canada | Princess Margaret Hospital | Toronto | Ontario |
Lead Sponsor | Collaborator |
---|---|
University Health Network, Toronto | Pfizer |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To assess the degree of modulation of the proliferation index, ki-67, in the primary tumor of OCC specimens following a short, preoperative course of PF-00299804 | 8-11 months | No | |
Secondary | To evaluate changes in tissue and blood-based biomarkers before, during and after treatment with PF-00299804 and attempt to correlate with gene expression changes, EGFR variant III mutation status, EGFR amplification and histopathological changes | 8-11 months | No | |
Secondary | To assess the relationship between pharmacokinetic parameters and molecular changes detected in OCC tumor specimens | 8-11 months | No | |
Secondary | To assess the safety and tolerability of pre-operative PF-00299804 | 8-11 months | Yes | |
Secondary | To quantitatively assess the effect of PF-00299804 on tumorigenic cells expressing CD44+/Lin- markers in paired OCC tumor specimens | 8-11 months | No | |
Secondary | To evaluate gene expression changes in tumor tissue before and after treatment with PF00299804 | 8-11 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01695122 -
Valproic Acid and Platinum-based Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Recruiting |
NCT05793151 -
Multi-Site Trial of Navigation vs Treatment as Usual for Delays in Starting Adjuvant Therapy
|
N/A | |
Recruiting |
NCT01958762 -
Screening for Cancers in the Oral CAvity
|
N/A | |
Recruiting |
NCT05429099 -
Mandibular Reconstruction Preplanning (ViPMR)
|
Phase 2/Phase 3 | |
Recruiting |
NCT05757817 -
Evaluation of the Benefit of a New Surgical Procedure According to IDEAL Recommendations for ORL Cancer Patients: the External Pudendal Flap Used as a New Free Flap for Oral Cavity/Oropharyngeal Reconstruction to Limit Donor Site Sequelae
|
N/A | |
Active, not recruiting |
NCT02586207 -
Pembrolizumab in Combination With CRT for LA-SCCHN
|
Phase 1 | |
Recruiting |
NCT04809324 -
Gross Examinations Versus Frozen Section for Assessment of Surgical Margins in Oral Cancers
|
N/A | |
Recruiting |
NCT02012699 -
Integrated Cancer Repository for Cancer Research
|
||
Terminated |
NCT03555721 -
CytID Analysis of Oral Lesions
|
||
Recruiting |
NCT05375266 -
Immune Biomarker Study for Head and Neck Cancer
|
||
Active, not recruiting |
NCT03082534 -
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT03096808 -
Adaptive Radiotherapy for Head and Neck Cancer
|
Phase 2 | |
Completed |
NCT00359645 -
Randomized Trial to Assess the Impact of a Screening Program on Upper Aerodigestive Tract Cancer Mortality in a High Risk Population
|
Phase 3 | |
Completed |
NCT02412241 -
Establishing Lymphedema and Fibrosis Measures in Oral Cancer Patients
|
N/A | |
Terminated |
NCT00934739 -
A Study of High-Risk Oral Cavity Cancer
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06407570 -
Dysphagia and Quality of Life in Patients With Oral Squamous Cell Carcinoma Before and After Treatment
|
||
Recruiting |
NCT05337631 -
Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy
|
||
Recruiting |
NCT05927220 -
WORST PATTERN OF INVASION IN ORAL SQUAMOUS CELL CARCINOMA
|
||
Recruiting |
NCT05369234 -
Effects of Oral Aloe Vera Juice on Chemotherapy and Radiation-induced Oral Mucositis and Esophagitis
|
Phase 3 | |
Completed |
NCT05056064 -
Efficacy of Swallowing Function After Early Postoperative Oral Exercise Among Patient With Oral Cavity Cancer Underwent Flap Reconstruction
|
N/A |